Kamala Harris

Joe Biden

Dean Phillips

Marianne Williamson

Donald Trump

Vivek Ramaswamy

Nikki Haley

Ron DeSantis

Cornel West

Robert F. Kennedy

2024 United States Presidential Election

Pfizer Inc said on Tuesday it will buy migraine drug maker Biohaven Pharmaceutical Holding Company Ltd for about $11.6 billion in cash, as the drugmaker seeks to beef up its portfolio ahead of patent losses for some cancer drugs. Through the deal, Pfizer will gain access to Biohaven's approved drug Rimegepant that belong to a class of migraine drugs known as calcitonin gene-related

Reuters

United Kingdom

Pfizer to buy migraine drugmaker Biohaven in $11.6 billion deal

Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. announced that both the companies have entered into an agreement wherein Pfizer will acquire Biohaven. Biohaven makes the NURTEC® ODT, used for migraine therapy in adults.

Media Bias/Fact Check

Times of India

India

Pfizer to acquire Biohaven by early 2023 for $11.6 billion

Ad Fontes Media

All Sides

The Woodbridge Company

Pfizer is starting to put its COVID-19 cash influx to use by spending $11.6 billion to venture deeper into a new treatment area. The New York vaccine and cancer drug

Associated Press News

Independent Media

United States

Pfizer to spend $11.6B on migraine treatment maker Biohaven

Pfizer is starting to put its COVID-19 cash influx to use by spending $11.6 billion to venture deeper into a new treatment area

abc News

The Walt Disney Company

Pfizer said on Tuesday it will buy migraine drug maker Biohaven Pharmaceutical Holding for about $11.6 billion in cash.

CNBC

Roberts family

Cash-rich Pfizer to pay $11.6 billion for Biohaven in biggest deal since 2016

By TOM MURPHY
AP Health WriterPfizer is spending $11.6 billion to buy the remaining portion of migraine treatment maker Biohaven Pharmaceuticals it does not already own.The New York drugmaker said Tuesday it will pay $148.50 in cash for each share of Biohaven, which makes Nurtec ODT for treating and preventing migraines and has another nasal spray under development.Pfizer says the price represents a 33% premium over Biohaven’s 90-day weighted av…

KVIA

News-Press & Gazette Company

Panama City

Bay County

Florida

Pfizer said it will buy migraine drug maker Biohaven Pharmaceutical Holding Company for about $11.6 billion in cash, as the drugmaker seeks to beef up its portfolio ahead of patent losses for some cancer drugs.

RTÉ

Government of Ireland

Ireland

Pfizer to buy Biohaven Pharmaceutical for $11.6 billion

Pfizer Inc said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceutical Holding Co , making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs. Read More

Financial Post

Leon Cooperman

Allianz

Canada

Pfizer to pay $11.6 bln for Biohaven to tap migraine market

Pfizer is spending $11.6 billion to buy the remaining portion of migraine treatment maker Biohaven Pharmaceuticals it does not already own.The New York drugmaker said Tuesday it will pay $148.50 in cash for each share of Biohaven, which makes Nurtec ODT for treating and preventing migraines and has another nasal spray under development.The price represents a 33% premium over Biohaven’s 90-day weighted average trading price of $111.70 for Biohave…

MY Northwest

Deseret Management Corporation

Tacoma

Pierce County

Washington

WPLG

Howard Buffett

Miami

Miami-Dade County

Cancer

Business

Pfizer

Coronavirus

Medical

New York City

US Economy

New York

WKMG

News 4 JAX

The Globe & Mail

Boston Herald

Click on Detroit

Medical Xpress

Bangor Daily News

Handelsblatt

MarketWatch

Al Arabiya

The Daily Star

WGN 9

The Detroit News

Khaleej Times

Business Wire

Financial Express

Market Wire News

Business Recorder

The Virginian Pilot

Boston Globe

صحيفة الاقتصادية

Bloomberg Linea

larepublica.co

Entrepreneur

CT Insider

Tribune India

La Información

Hartford Courant

Investor's Business Daily

STAT

Silicon Republic

MedCity News

Pennsylvania NY NJ Biotech Networks

biopharmadive.com

Pfizer will pay $148.50 cash for each share of Biohaven Pharmaceuticals that it does not already own. Nurtec, a drug that belongs to a new class of migraine medicines that target calcitonin gene-related peptide (CGRP) Pfizer will also get a stake in the company formed from Biohaven's other assets.

Pfizer to buy migraine drugmaker Biohaven in $11.6 billion deal

Coverage Details

Follow the money

Bias Distribution

Follow the money

Ownership

Similar News Topics

Follow the money

Similar News Topics